Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02337491
Title Pembrolizumab +/- Bevacizumab for Recurrent GBM
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute



high grade glioma



Bevacizumab + Pembrolizumab

Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
University of California, Los Angeles Los Angeles California 90095 United States Details
University of California, San Francisco San Francisco California 94143-0372 United States Details
Massachusetts General Hospital Boston Massachusetts 02113 United States Details
Dana-Farber Cancer Institute Boston Massachusetts 02215 United States Details
Memorial Sloan-Kettering Cancer New York New York 10021 United States Details
Duke University Medical Center Durham North Carolina 27710 United States Details
UT, MD Anderson Cancer Center Houston Texas 77030 United States Details
Huntsman Cancer Institute Salt Lake City Utah 84112 United States Details
*Shaded cells indicate that there was no data available from for the field